^
    Back
    Association details:
    Biomarker:TMB-L
    Cancer:Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Adv Clin Exp Med
    Title:

    The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants

    Published date:
    03/07/2023
    Excerpt:
    We aimed to explore the efficacy of ibrutinib in treating r/r CNSL patients, and whether genomic variants impact treatment outcomes….Patients who harbored simple genetic variants and those with a low tumor mutation burden (TMB; 2.39-5.56/Mb) responded swiftly and maintained remission for more than 10 months.
    DOI:
    10.17219/acem/159288